WHO discontinues hydroxychloroquine, lopinavir/ritonavir trial for Covid-19 treatment

Published By : Sourabha Parida | July 5, 2020 9:13 AM

Geneva, July 5: The World Health Organization (WHO) announced on Saturday that it was discontinuing hydroxychloroquine and lopinavir/ritonavir arms for its Solidarity Trial, citing little or no reduction in the mortality of hospitalised Covid-19 patients. The WHO said the decision was in light of the evidence from the Solidarity Trial interim results. "These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized Covid-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect," the WHO said in a press release, Xinhua reported. But the organization said this decision applies only to hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalised patients or as pre- or post-exposure prophylaxis for Covid-19. The Solidarity Trial was established by the WHO in March to find an effective Covid-19 treatment for hospitalised patients. It was originally designed to have five trial arms, including standard or usual care provided to Covid-19 patients, remdesivir, lopinavir/ritonavir combined, lopinavir/ritonavir combined with interferon beta, and hydroxychloroquine or chloroquine. By enrolling patients in multiple countries, the Solidarity Trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival. (IANS)

Prameya English Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp

More From Related News

Odisha: 10 hospitalized after eating wild mushroom curry in Rayagada’s village

SUM Hospital launches free Cy-Tb test

Odisha health department set for joint drive against water & vector borne diseases

Determined to saw off every drug cartel and protect our youth: Amit Shah

COVID-19 vaccines not linked to surge in heart attack deaths: Health Ministry

Odisha: Youth lead the way in ‘Menstrual Health Awareness’ at Berhampur University

AIIMS Bhubaneswar ranked 2nd best emerging medical college in India

Health Minister reviews Dengue, Malaria, Diarrhea, and Jaundice, orders for proactive measures

Diarrhea outbreak in Odisha under control: Health Minister

Food Safety Crackdown in Bhuban: Stalls Sealed and Fined Amid Public Health Crisis

International Yoga Day 2025: History and significance

OMC Launches Major Sickle Cell Anemia Awareness Drive in Odisha's Mining Belts

Diarrhea outbreak in Jajpur triggers panic; Six hotels sealed

Odisha: Expert teams deployed to tackle Diarrhoea outbreak in three districts

Odisha: Health Minister reviews Diarrhoea outbreak, urges rapid action

Odisha battles Diarrhoea outbreak; Minister Suraj Suryavanshi reviews situation in Jajpur

AIIMS Bhubaneswar to be accorded Centre of Excellence Status for Sickle Cell Disease Management

"From Research to Practice": GSICON 2025 Aims to Revolutionize Geriatric Medicine in India

Odisha Govt intensifies diarrhea prevention measures across five districts

Orissa High Court halts Asst. Prof Recruitment at AHPGIC Cuttack citing irregularity

Latest News

'Kyunki Saas Bhi Kabhi Bahu Thi' Is Sparking a...

Titan Shares Plunge: Jhunjhunwala Family Loses...

"Everyone Was Wearing Dark Sunglasses": Ashish...

Ratna Bhandar renovation completed in 95 days,...

BJP will grow stronger, play pivotal role in s...

Rasagolla Diwas: How Bhubaneswar-Cuttack Honor...

Niladri Bije: How a Sweet Rasagola Heals Divin...

WHO discontinues hydroxychloroquine, lopinavir/ritonavir trial for Covid-19 treatment

Prameya English Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp

You Might Also Like

Latest News

Campus Muse

Women

Science

Twin City